Druggable targets and targeted drugs: Enhancing the development of new therapeutics

Pharmacology

Volumn 82, Issue 4, 2008, Pages 239-244

  Billingsley, Melvin L ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Life Sciences Greenhouse of Central Pennsylvania   (United States)

Author keywords

Drug; Pharmacodynamics; Pharmacokinetics; Polydrug use; Structure activity relationships

Indexed keywords

DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; FUNCTIONAL GENOMICS; PRIORITY JOURNAL; PROTEOMICS; REVIEW;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; GENOMICS; HUMANS; PROTEOMICS; SYSTEMS BIOLOGY;

EID: 51849116307     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000157624     Document Type: Review

References (37)

1. Giovannetti GT, Jaggi G: Beyond Borders: Global Biotechnology Report. Ernst & Young, 2007, EJ0003.
2. Cuatrecasas P: Drug discovery in jeopardy. J Clin Invest 2006;116:2837-2842.
3. Giovannetti G, Harris T, Pittock W, Hobster J, Acosta T, Palnitkar U, Banerjee S, Friedman Y: Strategic Business Risk: Biotechnology. Ernst & Young/Oxford Analytica, 2008.
4. Wood AJJ: A proposal for radical changes in the drug-approval process. N Engl J Med 2006;355:618-623.
5. Borman S: Improving efficiency. Chem Eng News 2006;84:56-78.
6. Lipinski C, Hopkins A: Navigating chemical space for biology and medicine. Nature 2004;432:855-861.
7. Dobson C: Chemical space and biology. Nature 2004;432:824-828.
8. O'Connor K, Roth B: Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov 2005;4:1005-1014.
9. Sioud M: Main approaches to target discovery and validation. Methods Mol Biol 2007;306:1-12.
10. Kramer R, Cohen D: Functional genomics to new drug targets. Nat Rev Drug Discov 2004;3:965-972.
11. Hopkins AL, Groom CR: The druggable genome. Nat Rev Drug Discov 2002;1:727-730.
12. Goh K, Cusick ME, Valle D, Childs B, Vidal M, Barabasi A: The human disease network. Proc Natl Acad Sci USA 2007;104:8685-8690.
13. Schadt EE, Monks SA, Friend SH: A new paradigm for drug discovery: integrating clinical, genetic, genomic and molecular phenotype data to identify drug targets. Biochem Soc Trans 2003;31:437-443.
14. Sorace J, Canfield K, Russell S: Functional bioinformatics: the cellular response database. Front Biosci 1997;2:31-36.
15. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C, Reader V, Sweetman G, Bauer A, Bouwmeester T, Hopf C, Kruse U, Neubauer G, Ramsden N, Rick J, Kuster B, Drewes G: Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25:1035-1044.
16. Noble M, Endicott J, Johnson L: Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800-1805.
17. MacCoss M, Baillie T: Organic chemistry in drug discovery. Science 2004;303:1810-1813.
18. Kellenberger E, Muller P, Schalon C, Bret G, Foata N, Rognan D: sc-PDB: an annotated database of druggable binding sites from the Protein Data Bank. J Chem Inf Model 2006;4:717-727.
19. Landon MR, Lancia DR, Yu J, Thiel SC, Vajda S: Identification of hot spots within druggable binding regions by computational solvent mapping of proteins. J Med Chem 2007;50:1231-1240.
20. Zheng CJ, Han LY, Yap CW, Ji ZL, Cao ZW, Chen YZ: Therapeutic targets: progress of their exploration and investigation of their characteristics. Pharmacol Rev 2006;58:259-279.
21. Fishman MC, Porter JA: A new grammar for drug discovery. Nature 2005;437:491-493.
22. Yildirim MA, Goh K, Cusick ME, Barabasi AL, Vidal M: Drug-target network. Nat Biotechnol 2007;25:1119-1126.
23. Imoto S, Savoie CJ, Aburatani S, Kim S, Tashiro K, Kuhara S, Miyano S: Use of gene networks for identifying and validating drug targets. J Bioinform Comput Biol 2003;1:459-474.
24. Wolfe C, Kohane I, Butte A: Systematic survey reveals general applicability of 'guilt-byassociation' within gene coexpression networks. BMC Bioinformatics 2005;6:227-237.
25. Butte AJ, Kohane IS: Creation and implications of a phenome-genome network. Nat Biotechnol 2006;24:55-62.
26. Sawyers C: Targeted cancer therapy. Nature 2004;432:294-297.
27. Widakowich C, de Castro G, de Azambuja E, Dinh P, Awada A: Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007;12:1443-1455.
28. Dhillon AS, Hagan S, Rath O, Kolch W: MAP kinase signaling pathways in cancer. Oncogene 2007;26:3279-3290.
29. Clapéron A, Therrien M: KSR and CNK: two scaffolds regulating RAS-mediated RAF-activation. Oncogene 2007;26:3143-3158.
30. Kawakami S, Hashida M: Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet 2007;22:142-151.
31. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, Bacallado SA, Nguyen DN, Fuller J, Alvarez R, Borodovsky A, Borland T, Constien R, de Fougerolles A, Dorkin JR, Jayaprakash KN, Jayaraman M, John M, Koteliansky V, Manoharan M, Nechev L, Qin J, Racie T, Raitcheva D, Rajeev KG, Sah DWY, Soutschek J, Toudjarska I, Vornlocker H, Zimmerman TS, Langer R, Anderson DG: A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008;26:561-569.
32. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JR, Langer R: Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006;103:6315-6320.
33. Kutalik Z, Beckmann JS, Bergmann S: A modular approach for integrative analysis of large-scale gene-expression and drug-response data. Nat Biotechnol 2008;26:531-539.
34. Allen TM, Cullis PR: Drug delivery systems: entering the mainstream. Science 2004;303:1818-1822.
35. Suri SS, Fenniri H, Singh B: Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2007;1:16-22.
36. Bar H, Yacoby I, Benhar I: Killing cancer cells by targeted drug-carrying phage nanomedicines. BMC Biotechnol 2008;8:37-51.
37. Torchilin V: Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 2007;9:E128-E147.